Last reviewed · How we verify

NCT04699630

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

Completed Phase 2 Last updated 22 December 2025
What this trial tests

Phase 2 trial testing U3-1402 in Metastatic Breast Cancer in 121 participants. Completed in 9 April 2025.

Timeline
3 May 2021
Primary endpoint
9 April 2025
9 April 2025

Quick facts

Lead sponsorSCRI Development Innovations, LLC
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designsequential
Maskingnone
Primary purposetreatment
Enrollment121
Start date3 May 2021
Primary completion9 April 2025
Estimated completion9 April 2025
Sites11 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

SCRI Development Innovations, LLC — full company profile →

Who can join

18 and older, any sex, with Metastatic Breast Cancer or Locally Advanced Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 (patritumab deruxtecan) in patients with locally advanced or metastatic breast cancer (MBC).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Recent advances in therapeutic strategies for triple-negative breast cancer.
    Li Y, Zhang H, Merkher Y, Chen L, et al · · 2022 · cited 643× · PMID 36038913 · DOI 10.1186/s13045-022-01341-0
  2. Recent advances in targeted strategies for triple-negative breast cancer.
    Zhu S, Wu Y, Song B, Yi M, et al · · 2023 · cited 200× · PMID 37641116 · DOI 10.1186/s13045-023-01497-3
  3. Payload diversification: a key step in the development of antibody-drug conjugates.
    Conilh L, Sadilkova L, Viricel W, Dumontet C. · · 2023 · cited 152× · PMID 36650546 · DOI 10.1186/s13045-022-01397-y
  4. Targeting cancer with antibody-drug conjugates: Promises and challenges.
    Dean AQ, Luo S, Twomey JD, Zhang B. · · 2021 · cited 145× · PMID 34291723 · DOI 10.1080/19420862.2021.1951427
  5. Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.
    Krop IE, Masuda N, Mukohara T, Takahashi S, et al · · 2023 · cited 102× · PMID 37801674 · DOI 10.1200/jco.23.00882
  6. Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions.
    Chen YF, Xu YY, Shao ZM, Yu KD. · · 2023 · cited 93× · PMID 36357174 · DOI 10.1002/cac2.12387
  7. HER3 in cancer: from the bench to the bedside.
    Gandullo-Sánchez L, Ocaña A, Pandiella A. · · 2022 · cited 71× · PMID 36271429 · DOI 10.1186/s13046-022-02515-x
  8. Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges.
    Guidi L, Pellizzari G, Tarantino P, Valenza C, et al · · 2023 · cited 51× · PMID 36831473 · DOI 10.3390/cancers15041130

Verify or expand the search:

Other trials of U3-1402

Trials testing the same drug.

Other recruiting trials for Metastatic Breast Cancer

Currently open trials in the same condition.

Other SCRI Development Innovations, LLC trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04699630.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing